DaShenLin Pharmaceutical Group Co., Ltd.SSE: 603233

(603233)"DaShenLin Pharmaceutical Group Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes

· Issued by DaShenLin Pharmaceutical Group Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 603233 · · 4 pages · Chinese

Summary by 6ix AI

DaShenLin Pharmaceutical Group Co., Ltd. has announced the results of its convertible bonds conversion and the resulting changes in share capital. As of a specified date, a small portion of the convertible bonds has been converted into shares, with the majority remaining unconverted. The announcement details the total number of shares before and after the conversion, highlighting the increase in total share capital due to the conversion.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/603233dashenlin-pharmaceutical-group-co-ltdannouncement-on-conversion-results-of-convertible-bonds-and-share-changes

Release

Announcement on Conversion Results of Convertible Bonds and Share Changes

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

DaShenLin Pharmaceutical Group Co., Ltd. on 6ix

Story so far

Earlier from DaShenLin Pharmaceutical

Later from DaShenLin Pharmaceutical

All DaShenLin Pharmaceutical news releases